Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CLPP | Q16740 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.30 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185194 | 0.87 | TSHR (0.35) | TNIKTSHRHTR2AGRM2MAPK1 | |
| SCHEMBL16185237 | 0.81 | TSHR (0.33) | TNIKTSHRHTR2AGRM2CLPP | |
| SCHEMBL16185255 | 0.79 | TSHR (0.32) | TNIKTSHRHTR2AGRM2CLPP | |
| SCHEMBL16185282 | 0.77 | GRM2 (0.36) | TNIKHTR2AGRM2MAPK1CLPP | |
| SCHEMBL16185319 | 0.76 | TNIK (0.34) | TNIKHTR2AGRM2MAPK1AKR1B1 | |
| SCHEMBL16185316 | 0.74 | CLPP (0.38) | TNIKHTR2AGRM2AKR1B1CLPP | |
| SCHEMBL16185216 | 0.73 | GRM2 (0.38) | TNIKHTR2AGRM2MAPK1AKR1B1 | |
| SCHEMBL16185238 | 0.73 | CLPP (0.34) | TNIKHTR2AGRM2MAPK1CLPP | |
| SCHEMBL3907766 | 0.73 | ERCC1 (0.44) | TNIKHTR2AGRM2AKR1B1CLPP | |
| SCHEMBL16185233 | 0.73 | DRD4 (0.34) | TNIKTSHRGRM2TP53CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986291-B1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-27 | — | — | EP | claimed |
| EP-2986291-B1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-27 | — | — | EP | disclosed |
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014172188-A2 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | PNPO, TYMP, PDXK | TNIK 1114/4885TSHR 3844/4885HTR2A 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.